An NIH news release shared that a study on polycystic ovarian syndrome (polycystic ovary syndrome or PCOS) discovered that the condition might have two distinct subtypes based on genetic mutations. Through…
Botox Botox was first approved as a treatment for strabismus and blepharospasm, rare eye conditions, in 1989. Now, it is approved for 11 different conditions including cervical dystonia, chronic migraines,…
By engineering exosomes, Sarepta Therapeutics believes they can utilize gene therapies, RNA therapies, and gene editing without triggering an immune response in the body. They have just announced a new…
A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…
Ultragenyx Pharmaceutical's therapy, CRYSVITA, has recently been approved by the FDA for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors. This approval comes after…
According to a story from Cystic Fibrosis News Today, Eloxx Pharmaceuticals had just announced recently that it is officially re-opening enrollment for its phase 2 clinical study. This trial will…
According to LabioTech, a psoriasis drug developed by biotechnology company Affibody showed promising results in a Phase II clinical trial (AFFIRM-35). This trial, which consisted of 108 participants with…
According to a story from PR Newswire, the US Food and Drug Administration (FDA) has recently approved a new treatment for Dravet syndrome, a rare disorder that causes seizures and…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
